Epitope-Specific IgE Profiles are Predictive of Desensitization and Remission in the IMPACT Trial.

Baseline epitope IgE profiles can predict remission outcome for children undergoing pnOIT. Age and baseline peanut IgE remain important factors across models.

Notably, pnOIT prevented the epitope spreading of es-IgE observed in placebo-treated children, suggesting a treatment effect on the breadth of the allergic response that may be especially relevant in young children.

These profiles may help identify patients who are more likely to benefit from pnOIT.